Diatos acquires DaunoXome from Gilead for $4.7M
Paris, France-based Diatos SA has entered an exclusive licensing agreement with US firm Gilead Sciences on the worldwide development and commercialization rights to DaunoXome (daunorubicin, liposomal), which has been approved for AIDS/HIV-related Kaposi's sarcoma. It is sold by Gilead in more than 20 countries.
Under the terms of the deal, Diatos was granted exclusive global rights to the drug in Kaposi's sarcoma, as well as all other potential indications. In exchange, Gilead will receive upfront and milestone payments of up to $4.7 million, based on regulatory approval of new indications, and royalties on net sales.
The French group intends to seek approval from European regulatory authorities for the use of DaunoXome in acute leukemia and to market the drug for Kaposi's sarcoma in Europe and Brazil.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Today's issue
Company Spotlight
Copyright © The Pharma Letter 2025 | Headless Content Management with Blaze